These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 34889373

  • 21. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.
    Nickel RS, Hendrickson JE, Fasano RM, Meyer EK, Winkler AM, Yee MM, Lane PA, Jones YA, Pashankar FD, New T, Josephson CD, Stowell SR.
    Transfusion; 2016 Jan; 56(1):107-14. PubMed ID: 26509333
    [Abstract] [Full Text] [Related]

  • 22. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B, Padmanabhan S, Paley C, Chandrasekaran V.
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [Abstract] [Full Text] [Related]

  • 23. Relevance of blood groups in transfusion of sickle cell disease patients.
    Noizat-Pirenne F.
    C R Biol; 2013 Mar; 336(3):152-8. PubMed ID: 23643398
    [Abstract] [Full Text] [Related]

  • 24. RH genotype matching for transfusion support in sickle cell disease.
    Chou ST, Evans P, Vege S, Coleman SL, Friedman DF, Keller M, Westhoff CM.
    Blood; 2018 Sep 13; 132(11):1198-1207. PubMed ID: 30026182
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP.
    Pediatrics; 2003 Jun 13; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prevention of delayed hemolytic transfusion reaction.
    Pirenne F.
    Transfus Clin Biol; 2019 May 13; 26(2):99-101. PubMed ID: 30926306
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The role of molecular immunohematology in sickle cell disease.
    Chou ST, Westhoff CM.
    Transfus Apher Sci; 2011 Feb 13; 44(1):73-9. PubMed ID: 21277259
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
    Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM.
    Transfusion; 2019 May 13; 59(5):1698-1705. PubMed ID: 30848512
    [Abstract] [Full Text] [Related]

  • 36. Molecular characterization of GYPB and RH in donors in the American Rare Donor Program.
    Vege S, Westhoff CM.
    Immunohematology; 2006 May 13; 22(3):143-7. PubMed ID: 17105364
    [Abstract] [Full Text] [Related]

  • 37. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Cox JV, Steane E, Cunningham G, Frenkel EP.
    Arch Intern Med; 1988 Nov 13; 148(11):2485-9. PubMed ID: 3142382
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.